At a glance
- Originator GlaxoSmithKline
- Class
- Mechanism of Action Immunoglobulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypersensitivity
Most Recent Events
- 08 Dec 2003 No development reported - Preclinical for Allergy in United Kingdom (PO)
- 18 Sep 2001 New profile
- 18 Sep 2001 Preclinical development for Allergy in United Kingdom (PO)